Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 272,551 | 1,176,096 |
| Operating expenses: | ||
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 28,028 | 12,862 |
| Amortization of acquired intangible assets | 11,581 | 3,798 |
| Research and development | 100,873 | 108,973 |
| Selling, general and administrative | 86,183 | 80,961 |
| Change in the fair value of contingent consideration | — | (800) |
| Tangible asset impairment and losses on transactions, net | 927 | 77 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's D&A?
- PTC Therapeutics (PTCT) reported D&A of $11.58M in Q1 2026.
- How has PTC Therapeutics's D&A changed year-over-year?
- PTC Therapeutics's D&A increased by 204.9% year-over-year, from $3.8M to $11.58M.
- What is the long-term trend for PTC Therapeutics's D&A?
- Over 4 years (2021 to 2025), PTC Therapeutics's D&A has grown at a -18.0% compound annual growth rate (CAGR), from $54.75M to $24.74M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about PTC Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude